Why the study?
Diabetic cardiomyopathy is challenging to detect early because conventional biomarkers like natriuretic peptides and cardiac troponin I have limited predictive value or specificity in patients with type 2 diabetes mellitus.
Design
Review
Authors
Loading...
Caution against routine adoption for diabetic cardiomyopathy screening; leaves open prospective validation of listed biomarkers.
Novel circulating biomarkers such as galectin-3, ST2, and GDF-15 show promise for the early detection of diabetic cardiomyopathy compared to conventional markers like natriuretic peptides and troponin.
Ianoș et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: